

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletois Pharma Inc.

歌禮製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1672)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL
MEETING HELD ON JUNE 6, 2019**

References are made to the notice (the “**EGM Notice**”) of the extraordinary general meeting (the “**EGM**”) and the circular (the “**Circular**”) of Ascletois Pharma Inc. (the “**Company**”) both dated May 17, 2019. Unless otherwise indicated, capitalised terms used herein have the same meanings as those defined in the Circular.

POLL RESULTS OF EGM

At the EGM held on June 6, 2019, a poll was demanded by the chairman of the EGM for voting on the ordinary resolution (the “**Proposed Resolution**”) proposed at the EGM as set out in the EGM Notice.

As at the date of the EGM, the total number of issued Shares was 1,120,685,000 Shares, all of which entitled the holders to attend and vote for or against the Proposed Resolution at the EGM. There were no restrictions on any Shareholders to cast votes on any of the Proposed Resolution at the EGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of any of the Proposed Resolution at the EGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required under the Listing Rules to abstain from voting on the Proposed Resolution. None of the Shareholders have indicated in the Circular that they intended to vote against or to abstain from voting on any Proposed Resolution at the EGM.

The Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking at the EGM.

The poll results in respect of the Proposed Resolution were as follows:

Ordinary Resolution	No. of Votes (%)	
	For	Against
To adopt the Share Option Scheme	781,423,195 (94.996514%)	41,157,720 (5.003486%)

As more than 50% of the votes present at the EGM in person or by proxy were cast in favour of the above ordinary resolution, the Proposed Resolution was duly passed as an ordinary resolution of the Company.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People's Republic of China
June 6, 2019

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.